Tune in to this webinar recording from Wednesday, April 15, 2020. As the realizations of the Coronavirus sink in, one thing is certain – cannabis companies need to be leveraging good manufacturing practices, otherwise known as GMPs. GMPs are the practices required in order to conform to the guidelines recommended by the Food and Drug Administration (FDA). The FDA is the public health agency in the United States that controls the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices. While many companies in cannabis are already following these guidelines, some are not.

This panel explores the GMPs themselves, how companies can become compliant, how GMPs can be amplified to make certain that we are preventing the spread of COVID-19, and whether there are extra precautions that should be taken to keep cannabis consumers safe.

Panelists:

Andrew Kline, Director of Public Policy
National Cannabis Industry Association

Haley Brandsgard, Senior Quality and Compliance Manager
Mary’s Brands

Alena Rodriguez, Managing Director
Rm3 Labs

Trevor Morones, Founder
Control Point

Jen Komerda, Quality Assurance Manager
Wana Brands